US-based pharmaceutical company Amgen has announced a $900m expansion of its manufacturing facility in Ohio, increasing the total investment in Central Ohio to over $1.4bn.
The expansion will create 750 jobs, enhancing Amgen’s biomanufacturing capabilities in the US.
The company’s presence in Ohio began in June 2021 with an advanced manufacturing facility, initially generating 400 jobs.
Since the Tax Cuts and Jobs Act of 2017, Amgen has invested nearly $5bn in direct capital expenditures across the US, contributing approximately $12bn to the national economy.
The Ohio expansion is set to further strengthen the company’s global biomanufacturing network, building on its operational expertise and technological advancements.
Amgen chairman and CEO Robert Bradway said: “Amgen has been a leading US-based manufacturer of biologic medicines since 1988.
“Today’s investment reinforces our ongoing commitment to expanding US manufacturing and ensuring patients around the world have access to our innovative medicines.
“Ohio offers a supportive business climate, skilled workforce, and strategic location, making it an ideal choice for this next phase of our investment.”
Earlier this year, Amgen inaugurated a new drug substance facility in North Carolina.
The new facility represents a hybrid manufacturing approach that combines traditional stainless steel-fed batch processing with single-use technology.
It is designed to be more flexible and efficient, using 50% less water and supporting Amgen’s sustainability goal of achieving carbon neutrality by 2027.
The Ohio expansion comes on the heels of Amgen’s $1bn investment to construct a second manufacturing plant in Holly Springs, North Carolina.
Located in the Research Triangle, the Holly Springs site at Camp Helix Innovation Park is expected to employ manufacturing associates, engineers, and quality professionals.
Ohio Governor Mike DeWine said: “Ohio has built a strong foundation for economic development, which has led companies like Amgen to see Ohio as a premier destination for growth.
“We are happy to see Amgen deepen its commitment to our state and look forward to the innovation and economic impact it will drive.”
